ライフサイエンスコーパス: interferon-gamma

1 eath are promoted by the T helper 1 cytokine interferon gamma.

2 lls, express activation markers, and produce interferon gamma.

3 xposure to proinflammatory cytokines such as interferon-gamma.

4 factors from the GDNF family and a cytokine, interferon-gamma.

5 2 (CCR2), which was enhanced by exposure to interferon-gamma.

6 reased the secretion, but not expression, of interferon-gamma.

7 duce IL-4, including those that also produce interferon-gamma.

8 ainably inhibited the biological activity of interferon-gamma.

9 receiving metformin compared with controls (interferon gamma, 30.3 [11.5] vs 82.8 [18.8], P < .001;

10 A decreased the frequency of cells producing interferon gamma (6.79% vs 3.20%; P = .017) and tumor ne

11 independent both of the enteric flora and of interferon gamma, a key cytokine for the resolution of t

12 ith et al. (2016) demonstrate that mammalian interferon gamma activates an antimicrobial response wit

13 ould be detected by increased Granzyme B and Interferon gamma activity in the tumor as well as in cir

14 eaction was employed to detect low levels of interferon-gamma after primary peptide stimulation of CD

15 inhibits the secretion of IL-21, IL-17, and interferon gamma along with decreasing phosphorylated ST

16 ts through a mechanism which is dependent on interferon gamma and IL-17.

17 tion, but modulates inflammation by reducing interferon gamma and IL17 expression in lesioned central

18 sic protein peptide-specific cells secreting interferon gamma and interleukin (IL)-17 were significan

19 l responses (proliferation and production of interferon gamma and interleukin 10) to overlapping hepa

20 enotypic profile, as reflected by heightened interferon gamma and interleukin 17 (IL-17) production a

21 ide-specific capsule antibody titers, higher interferon gamma and interleukin 17 splenic responses, a

22 levels, negatively with Leishmania-specific interferon gamma and interleukin 2 levels, and negativel

23 Spot-forming cells (SFCs) of interferon gamma and interleukin 2, 4, 5, and 6 were cou

24 Interferon-gamma and granulocyte-macrophage colony-stimu

25 rentially secrete the Th1 and Th17 cytokines interferon-gamma and interleukin 17A, and are unresponsi

26 e pituitary and produced increased levels of interferon-gamma and interleukin-17 upon stimulation in

27 ls of the kidney were predominant sources of interferon-gamma and interleukin-17A, known to contribut

28 excessive production of cytokines, including interferon-gamma and interleukins 2, 6, and 10 (IL-2, IL

29 Increases of interferon-gamma and interleukins 6, 7, and 8 occurred o

30 delta T cells and stimulated them to secrete interferon-gamma and kill tumor cells.

31 these neuronal tissues, CD4 T cells secrete interferon-gamma and mediate local increase in vascular

32 proinflammatory responses on stimulation by interferon-gamma and oxidized low-density lipoprotein an

33 Protection was dependent on interferon-gamma and required early induction of robust

34 he adenosine receptor agonist NECA inhibited interferon-gamma and stimulated interleukin-6 production

35 e characterized by their capacity to produce interferon-gamma and their functional dependence on the

36 pression levels of TH17 cytokines but not of interferon-gamma and TNF, which lagged behind the amelio

37 lasma levels of tumor necrosis factor alpha, interferon gamma, and interferon gamma-induced protein 1

38 ents with CHB had weak T-cell proliferative, interferon gamma, and interleukin 10 responses to HBV, w

39 L22, CXCL8, and CXCL10; and T-cell cytokines interferon gamma, and interleukin 2, 10, and 17.

40 al and epithelial cells via interleukin 17A, interferon gamma, and tumor necrosis factor.

41 s in the brain, including interleukin-1beta, interferon-gamma, and fractalkine as well as a decreased

42 ry and profibrotic cytokines (interleukin-2, interferon-gamma, and interleukin-17) when CD73 was lack

43 ated decrease in tumor necrosis factor-beta, interferon-gamma, and monocyte chemoattractant protein-1

44 Endothelial activation transcripts, interferon-gamma, and NK transcripts showed association

45 uction of cytokines such as interferon-beta, interferon-gamma, and stimulating dendritic cells activa

46 interleukin (IL) 2, IL-4, IL-5, IL-7, IL-17, interferon-gamma, and tumor necrosis factor-alpha levels

47 of PTP1BDelta6 revealed a positive effect on interferon-gamma- and interleukin-4-induced JAK/STAT act

48 TH1 cells that secrete interferon-gamma are a major population of cells associa

49 l infections due to autoantibodies targeting interferon-gamma are an emerging medical problem.

50 xisting immunity, defined by high T-effector-interferon-gamma-associated gene expression, had improve

51 GATA2 deficiency and anti-interferon gamma autoantibodies also give rise to dissem

52 NO after stimulation with recombinant badger interferon gamma (bdIFNgamma) or a combination of bdIFNg

53 Production of interferon gamma by MAIT cells was dependent on monocyte

54 increased the production of IL17A, IL22, and interferon-gamma by cultured human colon CD3-negative, I

55 n during homeostasis and rapid production of interferon-gamma by NK cells after challenge.

56 The production of interferon-gamma by peripheral blood mononuclear cells i

57 interleukin-13, tumor necrosis factor-alpha, interferon-gamma, C-reactive protein, and procalcitonin

58 ine upregulates expression of genes encoding interferon-gamma, CD137 and granzyme B.

59 is, characterized by increased expression of interferon gamma, compared to wild-type mice exposed to

60 many pathways, including type I interferon, interferon gamma, complement activation, and nitric oxid

61 rable, except for significant differences in interferon-gamma, CXCL12, XCL1, interleukin-6 and interl

62 of pro-inflammatory cytokines and suppresses interferon-gamma-dependent priming of microglia.

63 delayed STAT1 dephosphorylation and enhanced interferon-gamma-driven responses.

64 dothelial activation, macrophage burden, and interferon-gamma effects accurately classify AMR and cor

65 men colonized by serotype III at enrollment, interferon gamma ELISPOT positivity was more common in t

66 ted to CMV-IE1 and CMV-pp65 were measured by interferon-gamma Elispot assay.

67 D4(+) T-cell responses were quantified using interferon gamma enzyme-linked immunosorbent spot assays

68 yme-linked immunosorbent assay (gpELISA) and interferon-gamma enzyme-linked immunospot (IFN-gamma ELI

69 lular cytokine staining, and fine mapping in interferon-gamma enzyme-linked immunospot assays.

70 IL8, tumor necrosis factor (TNF)-alpha, and interferon-gamma exposure.

71 the immunoproteasome in microglia following interferon-gamma exposure.

72 4, interleukin 2, tumor necrosis factor, and interferon gamma expression) of CD4(+) and CD8(+) T-cell

73 ted with interleukin 27, interleukin 21, and interferon gamma expression, rather than with FOXP3 or t

74 natural killer cells resulting in increased interferon-gamma expression and BTL.

75 C antigen presentation capacity, we measured interferon-gamma from co-cultures of DCs and autologous

76 ) T lymphocytes express more interleukin 17, interferon gamma, granulocyte-macrophage colony-stimulat

77 ment of NKp44 triggered NK cell secretion of interferon gamma (IFN)-gamma and tumor necrosis factor a

78 ification of chlamydial antigens that induce interferon gamma (IFN-) secretion by T cells from immune

79 Here we show that interferon gamma (IFN-?) protects human keratinocytes fr

80 of T-cell memory subsets, and frequencies of interferon gamma (IFN-gamma(+))/interleukin 2 (IL-2(+))/

81 uency of pp55-specific CD8 T cells producing interferon gamma (IFN-gamma) alone or dual IFN-gamma/gra

82 T cells, characterized by the production of interferon gamma (IFN-gamma) and interleukin 17 in patie

83 Interferon gamma (IFN-gamma) and interleukin 17A (IL-17A

84 immunosorbent assay [gpELISA]) and levels of interferon gamma (IFN-gamma) and interleukin 2 (IL-2; ma

85 We investigated the role of interferon gamma (IFN-gamma) and tumor necrosis factor a

86 We use interferon gamma (IFN-gamma) as a model analyte to demon

87 tivation and a decrease in the expression of interferon gamma (IFN-gamma) by DN T cells.

88 cation; however, macrophages stimulated with interferon gamma (IFN-gamma) can resist infection in vit

89 Interferon gamma (IFN-gamma) enzyme-linked immunospot as

90 experiments have shown a correlation between interferon gamma (IFN-gamma) expression and both surviva

91 Interferon gamma (IFN-gamma) is a dimerized soluble cyto

92 Interferon gamma (IFN-gamma) is an essential mediator of

93 M1 macrophages developed from interferon gamma (IFN-gamma) knockout (IFN-gamma-KO) mic

94 i-inflammatory effects through inhibition of interferon gamma (IFN-gamma) pathways.

95 We recently reported that interferon gamma (IFN-gamma) produced by CD8 T cells ult

96 Interferon gamma (IFN-gamma) produced by CMV-challenged

97 Induced interferon gamma (IFN-gamma) production and NKp46/NKp30

98 ripheral blood mononuclear cells (PBMCs) and interferon gamma (IFN-gamma) production were significant

99 The interferon gamma (IFN-gamma) recall response of splenocy

100 Interferon gamma (IFN-gamma) release assays (IGRAs) prov

101 Interferon gamma (IFN-gamma) stimulation resulted in an

102 Recombinant interferon gamma (IFN-gamma) therapy is inefficient, and

103 Interferon gamma (IFN-gamma) treatment enhanced in vivo

104 nhanced by interleukin (IL)-6, or reduced by interferon gamma (IFN-gamma), and that IL-6 regulation o

105 ed from the heparin-binding domain of murine interferon gamma (IFN-gamma), binds glycosaminoglycans t

106 e stimulated with P. falciparum antigen, and interferon gamma (IFN-gamma), interleukin 2, interleukin

107 D4(+) T cells expressing the three cytokines interferon gamma (IFN-gamma), tumor necrosis factor alph

108 terferon gamma inducible protein-10 (IP-10), interferon gamma (IFN-gamma), tumor necrosis factor supe

109 l in which the bacteria reside is exposed to interferon gamma (IFN-gamma), which leads to a tryptopha

110 me that has been confirmed to play a role in interferon gamma (IFN-gamma)-induced persistence, althou

111 JAK2 significantly decreases prolactin- and interferon gamma (IFN-gamma)-induced tyrosyl phosphoryla

112 cella infection; therefore, we infected anti-interferon gamma (IFN-gamma)-treated, or IFN-gamma(-/-)

113 ype, producing interleukin 17 (IL-17) and/or interferon gamma (IFN-gamma).

114 pathogenic T helper 1 (Th1) cells producing interferon-gamma (IFN-gamma) and granulocyte monocyte co

115 In addition, interferon-gamma (IFN-gamma) and interleukin 27 (IL-27)

116 iptional accessibility of the locus encoding interferon-gamma (IFN-gamma) and the loci encoding IL-5

117 e the production of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) and to initiate cytotoxicit

118 R2-derived class II-promiscuous peptides via interferon-gamma (IFN-gamma) enzyme-linked immunospot as

119 was needed to prevent premature induction of interferon-gamma (IFN-gamma) expression in T cells and t

120 Mutations in genes affecting interferon-gamma (IFN-gamma) immunity have contributed t

121 aneous candidiasis, whereas inborn errors of interferon-gamma (IFN-gamma) immunity underlie mycobacte

122 ker's yeasts, which suppressed production of interferon-gamma (IFN-gamma) in human whole blood cell a

123 ignificantly lower CD8+ T-cell production of interferon-gamma (IFN-gamma) in response to CMV antigens

124 Interferon-gamma (IFN-gamma) is a pleiotropic cytokine t

125 e gammadelta T cell subsets that make either interferon-gamma (IFN-gamma) or interleukin 17 (IL-17),

126 eport that Mal has a TLR-independent role in interferon-gamma (IFN-gamma) receptor signaling.

127 rived from Borrelia burgdorferi to stimulate interferon-gamma (IFN-gamma) release as an alternative t

128 Ex vivo interferon-gamma (IFN-gamma) responses to JEV in healthy

129 the PD-L1 pathway that negatively regulated interferon-gamma (IFN-gamma) secretion.

130 leading to HSC inhibition; in contrast, the interferon-gamma (IFN-gamma) signaling and its downstrea

131 open reading frames [ORFs] 1-3) was used in interferon-gamma (IFN-gamma) T-cell ELISpot assays.

132 eater expression level of IL-12, GM-CSF, and interferon-gamma (IFN-gamma) than either single treatmen

133 latory function depends on the production of interferon-gamma (IFN-gamma), but not by granzyme-mediat

134 by autoreactive CD4(+) and CD8(+) T cells of interferon-gamma (IFN-gamma), generally considered a pro

135 g expression of the proinflammatory cytokine interferon-gamma (IFN-gamma), via 3' untranslated region

136 Interferon-gamma (IFN-gamma)-induced PD-L1 up-regulation

137 ike 2 (Gabarapl2; also known as Gate-16), in interferon-gamma (IFN-gamma)-mediated antimicrobial resp

138 onstrate that Ct growth inhibition occurs by interferon-gamma (IFN-gamma)-mediated depletion of intra

139 crophages by proinflammatory signals such as interferon-gamma (IFN-gamma).

140 imulation with the pro-inflammatory cytokine interferon-gamma (IFN-gamma).

141 ant switch to being ILC1 cells that produced interferon-gamma (IFN-gamma).

142 acrophages, and reactivation is inhibited by interferon-gamma (IFN-gamma).

143 luding Th1 cells that preferentially produce interferon-gamma (IFN-gamma).

144 s, as well as low production of the cytokine interferon-gamma (IFN-gamma).

145 3 or UL123, and the T-cell activation marker interferon-gamma (IFN-gamma).

146 The interferon gamma+ (IFN-gamma+) and multifunctional CD4+

147 astric antral organoids) were incubated with interferon gamma (IFNG) or interferon beta (IFNB) and ex

148 th cytokine that induces NK cells to secrete interferon gamma (IFNG), which is quantified by an ELISA

149 ile analysis by RNA sequencing of subsets of interferon gamma (IFNG)-producing and non-producing cell

150 Here we show that interferon-gamma (IFNG) disrupts the RC of murine norovi

151 Interferon-gamma (IFNG) signaling activated the expressi

152 Interferon gamma (IFNgamma) and the epidermal growth fac

153 ted markers, including IL6, IP10, sCD14, and interferon gamma (IFNgamma) are reduced following TB tre

154 ponses to transient exposure to the cytokine interferon gamma (IFNgamma) by combining a systems-scale

155 TNFalpha), interleukin-1beta (IL-1beta), and interferon gamma (IFNgamma) has remained largely unexplo

156 Interferon gamma (IFNgamma) is a pleiotropic protein sec

157 Interferon gamma (IFNgamma) is the major proinflammatory

158 These neutrophils inhibit proliferation and interferon gamma (IFNgamma) production by T cells via a

159 As several lines of evidence suggest that interferon gamma (IFNgamma) production in CML patients m

160 PC-enriched corneas decreased frequencies of interferon gamma (IFNgamma)(+) effector T cells (Teffs),

161 s had significantly higher concentrations of interferon gamma (IFNgamma), interleukin1beta, interleuk

162 s cyclic GMP-AMP (cGAMP) synthase (cGAS) and interferon gamma (IFNgamma)-inducible protein 16 (IFI16)

163 regulation of the pro-inflammatory cytokine interferon-gamma (IFNgamma) and beta3 integrin signaling

164 ed bystander naive CD8(+) T cells to produce interferon-gamma (IFNgamma) and granzyme B (GZB) in the

165 polyinosinic-polycytidylic acid, and type-II interferon-gamma (IFNgamma) in human airway epithelial c

166 mmatory cytokines interleukin-17 (IL-17) and interferon-gamma (IFNgamma) in multiple models of infect

167 T cells to tumour rejection is unclear, but interferon-gamma (IFNgamma) is critical in most of the a

168 tion were linked to an increase in Abeta and interferon-gamma (IFNgamma) levels, and microgliosis.

169 Interferon-gamma (IFNgamma) neutralizing autoantibodies

170 rimary human hepatocytes were incubated with interferon-gamma (IFNgamma) or tumor necrosis factor-alp

171 hermore, the CD4(+) T cell-secreted cytokine interferon-gamma (IFNgamma) was found to be a key compon

172 tion of intratumoral Nrp1(-/-) Tregs produce interferon-gamma (IFNgamma), which drives the fragility

173 ells in vitro are the inflammatory cytokines interferon gamma, IL-1, and platelet-derived growth fact

174 e helper T cell type 1 (TH1)-related markers interferon-gamma, IL-15, and granulocyte-macrophage colo

175 pment of colitis and increased expression of interferon gamma in the small intestine compared to wild

176 r necrosis factor alpha, interleukin-10, and interferon-gamma in acute disease.

177 In addition, CD4 T cells produced less interferon-gamma in response to T-cell stimulation.

178 g inflammatory markers (e.g., TNF-alpha, and interferon-gamma) in the gut.

179 mutations resulted in a lack of response to interferon gamma, including insensitivity to its antipro

180 f HIV-1 Gag-specific CD8+ T cells expressing interferon gamma increased from baseline (0.09%) through

181 Stimulation by interferon-gamma increased intracellular localization of

182 [rs555212], Alpha-1-Antitrypsin[rs11846959], Interferon-Gamma Induced Protein 10[rs4256246] and von-W

183 ly 2.0-fold), CD69 (approximately 2.2-fold), interferon gamma-induced protein 10 (approximately 2.0-f

184 cted patients, and levels of interleukin 10, interferon gamma-induced protein 10 (IP-10), and hepatoc

185 necrosis factor alpha, interferon gamma, and interferon gamma-induced protein 10 were higher in patie

186 is factor alpha, interleukin 6 [IL-6], IL-8, interferon gamma-induced protein 10, IL-4, IL-9, IL-10,

187 Falpha [tumor necrosis factor alpha], IP-10 [interferon gamma-induced protein 10]), and proinflammato

188 Plasma interferon-gamma-induced protein 10 (IP-10) levels decli

189 The proinflammatory cytokine interferon-gamma-induced protein 10 (IP-10/CXCL10) was a

190 -2), monocyte chemotactic protein 2 (MCP-2), interferon gamma inducible protein-10 (IP-10), interfero

191 Other host factors, including interferon-gamma inducible factor 16 (IFI16), have been

192 Here we show that interferon-gamma inducible protein 16 (IFI16) cooperates

193 including interleukin 1 receptor antagonist, interferon gamma-inducible protein 10, hepatocyte growth

194 hted locus is a 100-kb region containing the interferon gamma-inducible protein 16 (IFI16) and absent

195 IFI16 (interferon gamma-inducible protein 16) recognizes nuclea

196 l transcripts, including CD16A signaling and interferon-gamma-inducible genes.

197 Plasma levels of interferon-gamma-inducible protein 10 (IP-10) were quant

198 immune activation associated with increased interferon-gamma-inducible protein 10, interleukin (IL)-

199 ately developed in infected neurons and that interferon gamma inhibited not only the CPE but also VZV

200 Nasosorption (but not NPA) levels of interferon gamma, interleukin 1beta, CCL5/RANTES, and in

201 x Plus: high-sensitivity C-reactive protein, interferon-gamma, interleukin (IL)-10, IL-12p70, IL-13,

202 ytokines levels were determined and included interferon-gamma, interleukin (IL)-1beta, IL-2, IL-4, IL

203 stander T, B, and NK cells; NKT cell-derived interferon-gamma, interleukin (IL)-4, and IL-21 cytokine

204 mokines such as tumor necrosis factor-alpha, interferon-gamma, interleukin 10 (IL-10), and CXCL9.

205 minimal production of the effector molecules interferon-gamma, interleukin-17, and interleukin-21.

206 locyte macrophage colony-stimulating factor, interferon-gamma, interleukin-1alpha (IL-1alpha) and IL-

207 They secrete interferon-gamma, interleukin-2, interleukin-10, and tum

208 >80% of the remodeled DNA aptamer targeting interferon-gamma (KD of 33 pM) survived in human serum a

209 Furthermore, neonatal and interferon gamma knockout mouse models of C. parvum infe

210 These changes did not occur in interferon-gamma knockout mice similarly treated, which

211 ied participants by quantitative QFT result (interferon-gamma <0.35 IU/mL, 0.35-4.00 IU/mL, and >4.00

212 d the efficacy of immunotherapy by enhancing interferon-gamma-mediated effects on antigen presentatio

213 inhibitory factor (MIF), monokine induced by interferon-gamma (MIG), and matrix metalloproteinase (MM

214 tained fewer CD4(+) and CD8(+) T cells, less interferon gamma, more neutrophils, more interleukin 10

215 om noncarriers contained on average 60% more interferon gamma mRNA (P = .031) and 19% less interleuki

216 or necrosis factor alpha (TNF-alpha) but not interferon gamma or interleukin 2 which had a differenti

217 ences in SFC counts between the 2 groups for interferon gamma or interleukin 2, 4, or 5 (all P > .05)

218 The proportion of T-helper type 1-prone (ie, interferon gamma- or tumor necrosis factor alpha-secreti

219 D4(+) T cells coproducing interleukin-10 and interferon gamma (P = .001), which were associated with

220 tumor necrosis factor-alpha (P = 0.040), and interferon-gamma (P = 0.03); and decreased oncostatin M

221 eralized mechanisms of inflammation, and the interferon-gamma pathway particularly.

222 interleukin-2, tumor necrosis factor-alpha, interferon-gamma, perforin, and CD107a expression) in 76

223 tial for EOMES(+) natural killer (NK) cells, interferon gamma-positive (IFN-gamma(+)) ILC1s, interleu

224 The magnitude of CD4(+) interferon-gamma producing T cells correlated with H5 an

225 s increased the number of tumor-infiltrating interferon gamma-producing natural killer (NK) cells.

226 gA antibodies, together with CTH522-specific interferon gamma-producing Th1 cells.

227 profile, although Noe chimera had more IFN (interferon)-gamma-producing NK cells, compared with wild

228 Pf-specific interferon-gamma-producing CD8 T cells were present at a

229 Using in vitro assays of interferon gamma production (enzyme-linked immunosorbent

230 Infection decreased interleukin 2 and interferon gamma production as well as the expression of

231 is issue, Overacre-Delgoffe et al. show that interferon gamma production by a subset of regulatory T

232 n directly enhanced T-cell receptor-mediated interferon gamma production by purified CD8(+) T cells b

233 reserved HSPC-NK killing, proliferation, and interferon gamma production capacity, whereas AZA dimini

234 sed regulatory T cells (Tregs) and activated interferon gamma production in these Tregs in the fetus.

235 NK cell activation, effector functions, and interferon gamma production, resulting in greater antibo

236 terleukin-1beta secretion, thereby promoting interferon-gamma production and T helper 1 (T(H)1) diffe

237 decreases the ability of iTregs to suppress interferon-gamma production by CD4(+)CD25(-) effector T

238 activating receptors normalized, and NK cell interferon-gamma production decreased after RG-101 dosin

239 , binding to CMV-specific HLA multimers, and interferon-gamma production.

240 multiple immune response pathways including Interferon-gamma production.

241 ments showed a correlation between sCD25 and interferon gamma (r = 0.562, P = .005), interleukin 10 (

242 ll-deficient mice, mice with deletion of the interferon gamma receptor (IFNGR) or IL10, and Rag1-/- m

243 Biallelic null mutations in genes encoding interferon gamma receptor 1 or 2 (IFNGR1 or IFNGR2) resu

244 We studied interferon-gamma receptor (IFN-gammaR) signaling in fibr

245 rine gammaherpesvirus68 (MHV68) infection in interferon gamma-receptor-deficient mice (IFNgammaR(-/-)

246 ured with enzyme-linked immunospot (ELISPOT) interferon gamma release assay at 20 weeks gestation in

247 plied either the tuberculin skin test or the interferon gamma release assay for diagnosis of LTBI and

248 Participants with a negative interferon gamma release assay to Nexvax2 peptides after

249 reatment oral gluten challenge per protocol, interferon gamma release assay to Nexvax2 peptides was n

250 Interferon gamma release assays (IGRAs) are blood-based

251 The value of quantitative interferon-gamma release assay results for predicting pr

252 Interferon-gamma release was significantly reduced when

253 ldren and trends in tuberculin skin test and interferon gamma-release assays.

254 s effects were due to a CD4 T-cell-dependent interferon gamma response and could be prevented by inhi

255 clearance was also associated with a reduced interferon gamma response to TLR4 (P = .038) and TLR7/8

256 w that APLNR interacts with JAK1, modulating interferon-gamma responses in tumours, and that its func

257 so demonstrated higher preexisting levels of interferon gamma-secreting CD4(+)CD69(+) T cells to 2009

258 d IL-12p40 and IL-10 secretion and increased interferon gamma secretion at 14 days p.i.

259 D-L1 and CD47, and confirmed that defects in interferon-gamma signalling caused resistance to immunot

260 n have key roles in antigen presentation and interferon-gamma signalling, and correlate with cytolyti

261 2 cells with tumor necrosis factor-alpha and interferon-gamma significantly increased paracellular pe

262 , interleukin 1beta (SMD 1.42; p=0.045), and interferon gamma (SMD 0.49; p=0.002) levels were higher

263 Mtb-containing phagosomes and identified an interferon-gamma-stimulated and Rab20-dependent membrane

264 The preS2-specific interferon gamma T-cell response increased between week

265 Functional HCV-specific interferon-gamma T-cell responses did not significantly

266 and natural killer cells, and activation of interferon-gamma, T-cell receptor, and expanded immune-r

267 molecules like granzyme B, and produced less interferon gamma than CD4 T cells induced by LCMV infect

268 CCL17, CXCL8, CXCL10; and interleukin 2 and interferon gamma than children who survived, and lower l

269 ible nitric oxide synthase, the M1 activator interferon gamma, the M2 activator interleukin 4, and M2

270 T) was conducted by measuring granulysin and interferon-gamma to confirm the causalities.

271 lls to release myeloid chemo-attractants and interferon gamma, to elicit myeloid infiltration and mac

272 transcripts (area under the curve=0.86), and interferon-gamma transcripts (area under the curve=0.84;

273 receptor domain-containing adaptor-inducing interferon-gamma (TRIF), factors critically involved in

274 concentrations of interleukin 2, 6, and 10, interferon gamma, tumor necrosis factor alpha, and C-rea

275 (IL)-1beta, IL-2, IL-6, IL-8, IL-10, IL-12, interferon gamma, tumor necrosis factor alpha, and granu

276 tuberculosis-specific CD4+ T-cell cytokine (interferon gamma, tumor necrosis factor alpha, and inter

277 rized, and polyfunctional (ie, they produced interferon gamma, tumor necrosis factor alpha, granulocy

278 oad panel of inflammatory markers, including interferon gamma, tumor necrosis factor alpha, interleuk

279 lobulin M and inflammatory markers including interferon gamma, tumor necrosis factor, CXCL13, and CXC

280 d proliferation of T cells and expression of interferon-gamma, tumor necrosis factor, and EOMES.

281 mbin complex, and cytokines (IL-1beta, IL-6, interferon-gamma, tumor necrosis factor-alpha, transform

282 ion-(CD25/CD28/CD54), type 1 T helper-(CD195/interferon-gamma/tumor necrosis factor-alpha/interleukin

283 n sarcoidosis, the proinflammatory cytokines interferon gamma, tumour necrosis factor and interleukin

284 cytotoxic granule constituents and produced interferon-gamma upon Fc-receptor engagement but not fol

285 reversion risk was inversely associated with interferon-gamma value at QFT conversion and was highest

286 By contrast, QFT conversion at very high interferon-gamma values (>4.00 IU/mL) warrants intensifi

287 QuantiFERON-TB Gold In-Tube (QFT) conversion interferon-gamma values and risk of subsequent active tu

288 ; p<0.0001), and compared with children with interferon-gamma values between 0.35-4.00 IU/mL (IRR 11.

289 I 0.4-1.1]), children with QFT conversion at interferon-gamma values between 0.35-4.00 IU/mL did not

290 However, QFT conversion at interferon-gamma values higher than 4.00 IU/mL was assoc

291 value at QFT conversion and was highest with interferon-gamma values less than 4.00 IU/mL (47 [77%] o

292 sion was common, following QFT conversion at interferon-gamma values up to 10 times the recommended t

293 ILC1-derived interferon-gamma was necessary and sufficient to drive p

294 -alpha and, to a lesser extent, IL-1beta and interferon-gamma were the most potent cytokines produced

295 The cytokines interleukin-21 and interferon-gamma, which are secreted from TH1 cells, wer

296 Moreover, angiotensin II infusion instigated interferon-gamma, which induced the expression of IDO an

297 phages is amplified by exposure to exogenous interferon-gamma, which prolongs and heightens inflammat

298 rtially restored by therapy with recombinant interferon-gamma, which suggested that metabolic process

299 or control requires effector lymphocytes and interferon-gamma, while antibodies targeting CD73 promot

300 nd that most aortic T cells express CCR5 and interferon-gamma with a unique combination of cell surfa